The needs of patients with psoriatic arthritis and psoriasis in the Pan-American region

Aims: The ability to predict response to treatment remains a key unmet need in psoriatic disease. We conducted a systematic review of studies relating to biomarkers associated with response to treatment in either psoriasis vulgaris (PsV) or psoriatic arthritis (PsA). Methods: A search was conducted in PubMed, Embase and the Cochrane library from their inception to 2 September 2020, and conference proceedings from four major rheumatology conferences. Original research articles studying pre-treatment biomarker levels associated with subsequent response to pharmacologic treatment in either PsV or PsA were included. Results: A total of 765 articles were retrieved and after review, 44 articles (22 relating to PsV and 22 to PsA) met the systematic review’s eligibility criteria. One study examined the response to methotrexate, one the response to tofacitinib and all the other studies to biologic disease-modifying antirheumatic drugs (DMARDs). Whilst several studies examined the HLA-C*06 allele in PsV, the results were conflicting. Interleukin (IL)-12 serum levels and polymorphisms in the IL-12B gene show promise as biomarkers of treatment response in PsV. Most, but not all, studies found that higher baseline levels of C-reactive protein (CRP) were associated with a better clinical response to treatment in patients with PsA. Conclusion: Several studies have identified biomarkers associated with subsequent response to treatment in psoriatic disease. However, due to the different types of biomarkers, treatments and outcome measures used, firm conclusions cannot be drawn. Further validation is needed before any of these biomarkers translate to clinical practice.

Download Full-text

Metabolomics Studies in Psoriatic Disease: A Review

Metabolites ◽

10.3390/metabo11060375 ◽

2021 ◽

Vol 11 (6) ◽

pp. 375

Author(s):

John Koussiouris ◽

Nikita Looby ◽

Melanie Anderson ◽

Vathany Kulasingam ◽

Vinod Chandran

Keyword(s):

Psoriatic Arthritis ◽

Small Molecules ◽

Web Of Science ◽

Citation Index ◽

Cochrane Central Register ◽

Psoriatic Disease ◽

Ovid Medline ◽

Standardized Protocol ◽

Central Register ◽

Endogenous Metabolites

Metabolomics investigates a broad range of small molecules, allowing researchers to understand disease-related changes downstream of the genome and proteome in response to external environmental stimuli. It is an emerging technology that holds promise in identifying biomarkers and informing the practice of precision medicine. In this review, we summarize the studies that have examined endogenous metabolites in patients with psoriasis and/or psoriatic arthritis using nuclear magnetic resonance (NMR) or mass spectrometry (MS) and were published through 26 January 2021. A standardized protocol was used for extracting data from full-text articles identified by searching OVID Medline ALL, OVID Embase, OVID Cochrane Central Register of Controlled Trials and BIOSIS Citation Index in Web of Science. Thirty-two studies were identified, investigating various sample matrices and employing a wide variety of methods for each step of the metabolomics workflow. The vast majority of studies identified metabolites, mostly amino acids and lipids that may be associated with psoriasis diagnosis and activity. Further exploration is needed to identify and validate metabolomic biomarkers that can accurately and reliably predict which psoriasis patients will develop psoriatic arthritis, differentiate psoriatic arthritis patients from patients with other inflammatory arthritides and measure psoriatic arthritis activity.

Download Full-text

THU0443 Unmet Needs in Psoriatic Arthritis: One Third of The Patients with Quiescent Disease According To The Rheumatologist's Opinion Do Not Achieve Minimal Disease Activity: Table 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.2124 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 351.2-352

Author(s):

L.J. Van Mens ◽

A.W. van Kuijk ◽

D.L. Baeten

Keyword(s):

Psoriatic Arthritis ◽

Disease Activity ◽

Unmet Needs ◽

Minimal Disease Activity ◽

Minimal Disease ◽

Quiescent Disease

Download Full-text

Volumetric Bone Mineral Density Measured by HR-pQCT in Patients with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

Healthcare ◽

10.3390/healthcare9081056 ◽

2021 ◽

Vol 9 (8) ◽

pp. 1056

Author(s):

Yu-Wen Huang ◽

Jing-Wun Lu ◽

Tai-Li Chen

Keyword(s):

Bone Mineral Density ◽

Systematic Review ◽

Psoriatic Arthritis ◽

Sequential Analysis ◽

Meta Analysis ◽

Bone Microstructure ◽

Trial Sequential Analysis ◽

Volumetric Bone Mineral Density ◽

Mineral Density ◽

Psoriatic Disease

Bone health in psoriasis and psoriatic arthritis has been emphasized in recent years. Novel imaging modalities allow investigations into volumetric bone mineral density (vBMD) and bone microstructure in psoriatic patients. However, literature regarding vBMD measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) is inconclusive. We conducted a systematic review and meta-analysis to evaluate vBMD in patients with psoriatic disease. We searched PubMed, EMBASE, Web of Science, and Cochrane Library for relevant observational studies. A random-effects meta-analysis with trial sequential analysis (TSA) was performed. The pooled mean difference (MD) and 95% confidence interval (CI) were calculated. Five studies with 780 patients were included. Patients with psoriatic disease showed a lower average vBMD than controls (MD −14.90; 95% CI −22.90 to −6.89; TSA-adjusted CI −23.77 to −6.03; I2 = 41%). Trabecular vBMD and cortical vBMD results were inconclusive because of the small sample size. Patients recruited in Asia and those whose vBMD were measured at the distal radius exhibited a lower average vBMD than controls. Further research should clarify the association of psoriasis with bone microstructure and the underlying pathophysiology.

Download Full-text